Sirtratumab  (Synonyms: AGS15C; Ha15-10ac12; Ha15-10ac12.1)

Sirtratumab (AGS15C; Ha15-10ac12; Ha15-10ac12.1) is a SLITRK6-specific humanized IgG2 monoclonal antibody, and serves as the parental antibody of the ADC ASG-15ME (HY-P99595). Sirtratumab is applicable for cancer research^[1].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

SLITRK6

Sirtratumab (0.00067-40 nmol/L; overnight at 4°C) binds with high affinity to SLITRK6 expressed on SW-780 bladder transitional cell carcinoma cells, with a K_d of 0.015 nmol/L^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

84189  [NCBI]

Q9H5Y7

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146 kDa

1824663-82-2

Liquid

Colorless to light yellow

[Sirtratumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Flow Cytometry analysis of SK-N-SH cells labelling SLITRK6 (red) with Sirtratumab (anti-SLITRK6) (HY-P99964). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 kappa (HY-P99002). Black-Unlabelled control, cells without incubation with primary antibody.
• 
  Immobilized HY-P77208 SLITRK6 Protein, Human (HEK293, His) can bind Sirtratumab. The EC₅₀ for this effect is 19.86 ng/mL.

• [1]. Morrison K, et al. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016;15(6):1301-1310.  [Content Brief]